Multicenter randomized controlled phase 2 trial to evaluate AM-125 in the treatment of acute peripheral vertigo following neurosurgery (TRAVERS)
Phase of Trial: Phase II
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs Betahistine (Primary) ; Betahistine
- Indications Vertigo
- Focus Proof of concept; Therapeutic Use
- Acronyms TRAVERS
- Sponsors Auris Medical
- 15 Aug 2019 According to an Auris Medical media release, an interim analysis is expected for the fourth quarter of 2019 or the first quarter of 2020.
- 30 Jul 2019 Status changed from not yet recruiting to recruiting, according to an Auris Medical media release.
- 30 Jul 2019 According to an Auris Medical media release, first patient has been randomized in this trial.